Rare disease drug developer pays $6M after DoJ alleges ‘kickback’ scheme around lab tests

The payment will go to Medicare and Medicaid programs that the Justice Department alleges covered one of Ultragenyx’s drugs; the company says its free-testing program saved those programs money.
Click here to view original post

Advertisement — Advertise with Biotech Networks